FDA Greenlights Merck's First-Ever Cholesterol Pill

The U.S. Food and Drug Administration (FDA) has approved Merck's novel cholesterol pill, Lipfendra, marking a significant milestone as the first drug of its kind to gain regulatory clearance. This oral PCSK9 inhibitor offers a new alternative for patients suffering from hypercholesterolemia, characterized by elevated levels of LDL or "bad" cholesterol.

The once-daily pill works by inhibiting the PCSK9 protein, a key regulator of cholesterol levels, providing a distinct mechanism compared to older oral statins. Clinical trials demonstrated that Lipfendra effectively reduced LDL cholesterol in a diverse patient population, including those with familial hypercholesterolemia and those already on statin therapy.

This FDA approval is particularly strategic for Merck, as it seeks to broaden its product offerings in anticipation of Keytruda's patent expirations starting in 2028. The introduction of Lipfendra diversifies the company's portfolio, moving beyond its reliance on the blockbuster cancer treatment.

Lipfendra enters a market currently dominated by injectable PCSK9 inhibitors such as Amgen's Repatha and Regeneron/Sanofi's Praluent. Analysts had previously projected significant sales potential for Merck's new oral treatment, with some estimates reaching into the tens of billions of dollars. The drug's review was expedited through the FDA commissioner's National Priority Voucher program.